Interview with Mark Fladrich, Managing Director, Australia & New Zealand,…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
Address: 5 Alma Road, North Ryde NSW 2113,Australia
Tel: +61 2 9978 3500
Web: http://www.astrazeneca.com.au/home/
AstraZeneca Australia is engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians.
AstraZeneca is one of Australia’s largest private sector investors in medical research and development (R&D) and has, invested more than $250 million in Australia in the last decade.
It is the largest national manufacturer of pharmaceuticals in Australia, providing $1.2 billion of medicines to the local market and $200 million in exports.
AstraZeneca currently involved in more than 50 clinical trials at over 200 sites across Australia, investigating potential new treatments in the areas of oncology, cardiovascular, diabetes, infection, gastrointestinal, neuroscience, respiratory, and inflammation.
The company employs more than 900 people in Australia and is committed to being recognised as an ‘Employer of Choice’.
AstraZeneca couples a global reach with local knowledge that stems from its long heritage in Australia that dates back to 1957.
AstraZeneca focuses on the following health care areas: cardiovascular, diabetes, gastrointestinal, neuroscience, oncology, respiratory, anaesthesia and pain management.
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Would you please introduce The Pharmacy Guild to our readers, giving an insight in its function and its membership? We are the premium body representing community pharmacies in Australia, about…
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities,…
Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike…
You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
See our Cookie Privacy Policy Here
